Trend followers stage recovery as stretched S&P, Nasdaq longs fuel gains
Jean M. Franchi, Chief Financial Officer of Disc Medicine, Inc. (NASDAQ:IRON), a biotechnology company with a market capitalization of $1.99 billion, sold 2,000 shares of common stock on July 10, 2025, at a price of $57.50, totaling $115,000. According to InvestingPro data, the stock has shown strong momentum with a 9% return over the past week. Following the transaction, Franchi directly owns 65,530 shares of Disc Medicine. The sale was executed under a Rule 10b5-1 trading plan adopted on March 10, 2025. InvestingPro analysis shows the company maintains strong liquidity with a current ratio of 37.65, while analysts set price targets ranging from $75 to $132, suggesting potential upside. Get access to 10+ additional exclusive ProTips and comprehensive analysis with an InvestingPro subscription.
In other recent news, Disc Medicine has made several notable announcements and updates. The company has appointed Nadim Ahmed to its board of directors, effective immediately. Ahmed, who is currently the President and CEO of Cullinan Therapeutics, brings over 25 years of leadership experience in the pharmaceutical industry. In financial updates, Morgan Stanley (NYSE:MS) initiated coverage on Disc Medicine with an Overweight rating, highlighting the potential of bitopertin to reach the market faster through an accelerated approval process. Morgan Stanley also projects a 2026 launch for bitopertin with significant peak sales potential in the U.S. Meanwhile, H.C. Wainwright reaffirmed its Buy rating and $118 price target, emphasizing progress with bitopertin for Erythropoietic Protoporphyria (EPP) and the potential of DISC-0974 in treating myelofibrosis. BMO Capital reiterated its Outperform rating, noting Disc Medicine’s consistent progress across its pipeline and the ongoing NDA submission process for bitopertin. The company is also advancing its efforts in patient identification and payer engagement as part of its commercialization strategy.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.